Jack A. Khattar
President, CEO at Supernus Pharmaceuticals Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Supernus Pharmaceuticals Inc., 3 years.
Supernus Pharmaceuticals Inc.
Director · President, CEO
Cognition Therapeutics Inc.
Director
Chief executive roles
Supernus Pharmaceuticals Inc.
· President, CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2024 | Supernus Pharmaceuticals Inc. | Option exercise | +21,000 | — | — |
| Sep 3, 2024 | Supernus Pharmaceuticals Inc. | Shares withheld for tax | −10,045 | $34.90 | $350,571 |
| Jun 7, 2024 | Cognition Therapeutics Inc. | Grant or award | +8,500 | — | — |
| Feb 28, 2024 | Supernus Pharmaceuticals Inc. | Option exercise | +35,000 | — | — |
| Feb 28, 2024 | Supernus Pharmaceuticals Inc. | Shares withheld for tax | −16,788 | $27.94 | $469,057 |
| Feb 12, 2024 | Supernus Pharmaceuticals Inc. | Other | +16,500 | — | — |
| Feb 12, 2024 | Supernus Pharmaceuticals Inc. | Other | −16,500 | — | — |
| Dec 22, 2023 | Supernus Pharmaceuticals Inc. | Option exercise | +25,000 | — | — |
| Dec 22, 2023 | Supernus Pharmaceuticals Inc. | Shares withheld for tax | −11,958 | $27.66 | $330,758 |
| Sep 7, 2023 | Supernus Pharmaceuticals Inc. | Option exercise | +35,000 | — | — |
| Sep 7, 2023 | Supernus Pharmaceuticals Inc. | Shares withheld for tax | −16,804 | $32.10 | $539,408 |
| Jun 9, 2023 | Cognition Therapeutics Inc. | Grant or award | +6,000 | — | — |
| May 11, 2023 | Supernus Pharmaceuticals Inc. | Option exercise | +31,250 | — | — |
| May 11, 2023 | Supernus Pharmaceuticals Inc. | Shares withheld for tax | −15,005 | $36.47 | $547,232 |
| Mar 14, 2023 | Supernus Pharmaceuticals Inc. | Option exercise | +20,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.